Cargando…

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Detalles Bibliográficos
Autores principales:	Rayer, Cassandra, Nachury, Maria, Bourreille, Arnaud, Roblin, Xavier, Peyrin-Biroulet, Laurent, Viennot, Stephanie, Flamant, Mathurin, Laharie, David, Caron, Bénédicte, Dewitte, Marie, Siproudhis, Laurent, Fumery, Mathurin, Bouguen, Guillaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896746/ https://www.ncbi.nlm.nih.gov/pubmed/36732693 http://dx.doi.org/10.1186/s12876-022-02636-9

Ejemplares similares

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Managing complex perianal disease after anti-TNF failure: Where to go next?
por: Yzet, Clare, et al.
Publicado: (2022)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab
por: Roblin, Xavier, et al.
Publicado: (2015)

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2023)

Transmembrane TNF-α: structure, function and interaction with anti-TNF agents
por: Horiuchi, Takahiko, et al.
Publicado: (2010)

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
por: Albshesh, Ahmad, et al.
Publicado: (2023)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Inflammatory bowel disease: towards a personalized medicine
por: Flamant, Mathurin, et al.
Publicado: (2018)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
por: Yoo, Hyun Kyeong, et al.
Publicado: (2022)

Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents
por: Wang, Qiaolei, et al.
Publicado: (2020)

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2021)

Common Adverse Effects of Anti-TNF Agents on Gestation
por: Fasoulakis, Zacharias, et al.
Publicado: (2016)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
por: Lelong, Margaux, et al.
Publicado: (2022)

Use of imaging modalities for decision-making in inflammatory bowel disease
por: Nancey, Stéphane, et al.
Publicado: (2023)

Can We Predict the Efficacy of Anti-TNF-α Agents?
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2017)

Tuberculous Tonsillitis in a Patient Treated with an Anti-TNF Agent
por: Ferreira, Sara, et al.
Publicado: (2017)

Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)

Comparison of the risk of heart failure in psoriasis patients using anti‐TNF α inhibitors and ustekinumab
por: Han, Ju Hee, et al.
Publicado: (2022)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
por: Sugiyama, Yuya, et al.
Publicado: (2023)

Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
por: Tynjälä, P, et al.
Publicado: (2008)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

Understanding the biology and use of anti-TNF agents in JIA – interim results
por: Lovell, Daniel J, et al.
Publicado: (2012)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
por: Fragoulakis, Vasilis, et al.
Publicado: (2015)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents
por: Clark, Ian A., et al.
Publicado: (2016)

DISSEMINATED GRANULOMA ANNULARE: A CUTANEOUS ADVERSE EFFECT OF ANTI-TNF AGENTS
por: Ratnarathorn, Mondhipa, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_egdf1euj5u4csc9q60sk1sukn2